Clinical Trial

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
Trial Details
NCT Number NCT07104643
Lead Sponsor TYK Medicines, Inc
Conditions mCRPC
Enrollment 48 participants
Start Date 2025-08
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-08-05